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Notch signaling in the cardiovascular system is important during embryonic development,
vascular repair of injury, and vascular pathology in humans. The vascular smooth muscle
cell (VSMC) expresses multiple Notch receptors throughout its life cycle, and responds to
Notch ligands as a regulatorymechanism of differentiation, recruitment to growing vessels,
and maturation.The goal of this review is to provide an overview of the current understand-
ing of themolecular basis for Notch regulation ofVSMC phenotype. Further, wewill explore
Notch interaction with other signaling pathways important in VSMC.
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INTRODUCTION
Notch receptors are type-1 transmembrane proteins that regulate
cell differentiation during embryogenesis and tissue injury and
repair. Notch receptors are activated through tightly controlled
juxtacrine interactionswith transmembrane proteins of the Jagged
(Jag) or Delta-like (Dll) families of ligands (Figure 1). In mam-
mals, expression of the four Notch receptors (Notch1, Notch2,
Notch3, and Notch4) and ﬁve ligands (Jag-1, Jag-2, Dll-1, Dll-
3, and Dll-4) varies signiﬁcantly among cell types and changes
in response to environmental cues within the surrounding tissue
(Andersson et al., 2011; de la Pompa and Epstein, 2012). After
translation, Notch precursor proteins traverse the Golgi appara-
tus where they undergo S1 cleavage by a furin-like convertase in
the trans-Golgi network (Lake et al., 2009). This maturation step
creates a heterodimer consisting of a large extracellular domain
(ECD) comprised mainly of repeating EGF-like repeats linked
through non-covalent bonds to a smaller domain consisting of
the transmembrane and intracellular portion of the receptor, aptly
referred to as the Notch extracellular truncation (NEXT; Mumm
et al., 2000). The Notch proteinsmay be subjected to N-linked gly-
cosylationby fringe enzymes (Lunatic,manic, radical) before being
presented as a mature receptor on the cell surface. The interaction
of Notch receptors with Jag or Dll ligands results in a conforma-
tional change in the ECDof the receptor that exposes a cleavage site
for the metalloprotease ADAM17 to initiate S2 cleavage; thereby
liberating the ECD from the cell surface. Endocytosis of the lig-
and/ECD complex occurs in the ligand-presenting cell and the
mechanism and importance of this event is currently the subject
of much debate.
Full activation of Notch receptors is achieved upon S3 cleavage
of NEXT by presenilin, the proteolytic subunit of the γ-secretase
complex (De Strooper et al., 1999), to liberate the intracellular
domain (ICD).Once released from theplasmamembrane, the ICD
translocates into the nucleus where it binds to the transcriptional
repressor RBP-J (CBF1) the mammalian homolog of suppressor
of hairless (SuH) in Drosophila (Tanigaki and Honjo, 2010). The
transcriptional repressor activity of CBF1 is alleviated through
the formation of a multi-protein complex involving NotchICD,
CBF1, and proteins of the Mastermind-like family (MAML; Nam
et al., 2007;Kovall, 2008). Formation of the ternary complex causes
displacement of the CBF1 associated co-repressor SMRT and his-
tone deacetylases (HDAC; Kao et al., 1998), while simultaneously
binding to Ski-interacting protein SKIP (Zhou et al., 2000), his-
tone acetyltransferases p300 and PCAF (Wallberg et al., 2002),
and elongation factor CyclinT1:CDK9 (Chopra et al., 2009) to
assist with transcriptional initiation. The NotchICD-containing
activator complex goes on to promote transcription of down-
stream gene targets including Hairy enhancer-of-split (HES) and
Hairy/enhancer-of-split related with YRPW motif (HEY, also
called HRT, HERP, HESR; Iso et al., 2003) through CBF1 bind-
ing to CGTGGGAA motifs in the promoter regions of these
genes (Tun et al., 1994). Turning off Notch signaling begins with
degradation of the active transcriptional complex through recruit-
ment of CyclinC:CDK8 by MAML. CyclinC:CDK8 recruitment
to the complex promotes hyperphosphorylation of NotchICD
within its PEST domain and targets the protein for Fbw7/Sel10
E3 ubiquitin ligase-dependent degradation (Fryer et al., 2004).
Other kinases that promote NotchICD turnover through phos-
phorylation include theWnt pathway associated enzyme glycogen
synthase kinase 3β (GSK-3β; Espinosa et al., 2003) and the ubiq-
uitously expressed casein kinase 2 (Ranganathan et al., 2011).
Figure 1 provides an overview of the canonical Notch signaling
pathway.
NOTCH SIGNALING IN CARDIOVASCULAR DEVELOPMENT
During cardiovascular development, perturbations in the expres-
sion of Notch pathway components result in profound vascular
malformations, and this has been extensively addressed using
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FIGURE 1 | Overview of Notch signaling. Notch signaling is activated when
a transmembrane ligand of the Delta–Serrate Lag (DSL) family (1) interacts
with the EGF-like repeats of the extracellular domain of Notch receptors (2) on
an adjacent cell. Ligand/receptor interactions induce a conformational change
in the receptor, exposing critical sites for ADAM17 (S2) and γ-secretase (S3)
cleavage of the Notch receptor (3). Cleavage of Notch receptors results in
liberation and translocation of the intracellular domain (ICD) to the nucleus (4)
while the extracellular domain (ECD) is endocytosed by the ligand-bearing cell
(5). In the nucleus, the RAM domain of NotchICD binds to transcriptional
repressor CBF1, causing displacement of associated co-repressors and
recruitment of Mastermind-like (MAML) and other co-activators (6) to initiate
transcription of Notch/CBF1 regulated downstream genes (7). Turning off
Notch signaling begins with recruitment of CDK8 by MAML to the active
complex, thereby causing phosphorylation of NotchICD within its PEST
domain. Phosphorylation causes recruitment of E3 ubiquitin ligase Fbw7 for
ubiquitination (8) and proteosome degradation of (9) of NotchICD, thereby
destabilizing the activator complex and allowing CBF1 to re-associate with
co-repressors.
mouse genetic models (Table 1). Targeted deletion of Notch1,
Notch2, Notch3, Jag-1, Dll-1, and Dll-4 all lead to a variety of vas-
cular defects. Both Notch2 and Notch3 mutations lead to defects
in vascular smooth muscle cell (VSMC) development, showing
their requirement for expansion and maturation of the mural cell
population. Although endothelial cell Notch ligands are impor-
tant activators of VSMC development (Xue et al., 1999; High et al.,
2008), VSMC also signal homotypically through Notch. Deletion
of Jag-1 in smooth muscle cells using SM22α regulatory elements
leads to loss of VSMC differentiation and patent ductus arteriosus
(Figure 2). In these mice, the ductus arteriosus and descending
aorta had fewer mural cells that could be molecularly identiﬁed
as VSMC, suggesting a defect in propagation of the Jag-1/Notch
signal throughout the medial vascular wall (Feng et al., 2010).
Several signaling pathways and transcription factors are impor-
tant in dictating the phenotypic state (i.e., proliferative versus
contractile) of VSMC, some of which include: serum response
factor (SRF)/myocardin (Manabe and Owens, 2001; Camoretti-
Mercado et al., 2003; Miano et al., 2007), PDGF (Marmur et al.,
1992; Thommes et al., 1996), TGF-β (Ikedo et al., 2003; Tang
et al., 2010), GATA-6 (Wada et al., 2000), IGF-I (Thommes
et al., 1996), FGF-2 (Segev et al., 2002), endothelin-1 (Hahn
et al., 1992), and nitric oxide (Grange et al., 2001). In the last
decade or so, a great deal of evidence has emerged supporting a
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Table 1 | Notch cardiovascular phenotypes in mouse models.
Gene Normal cardiovascular
expression
Genetic mouse model and cardiovascular
phenotype
Survival Reference
Notch1 Arterial endothelium Global null: collapsed aorta and cardinal vein,
reduced sprouting angiogenesis, abnormal yolk
sac vasculature, and vascular remodeling
Lethal at E9.0–9.5 Krebs et al. (2000, 2010)
Vascular smooth
muscle
Endocardium EC gain of function: enlarged heart and reduced
vessel diameter, abnormal remodeling of yolk
sac vasculature, hemorrhaging
Lethal at E9.5
Atrioventricular canal
Notch2 Cardiac neural
crest-derived VSMC
Global null: reduced pulmonary artery and aortic
VSMC proliferation, defects in eye vasculature
Lethal at E11.5 Krebs et al. (2000), Varadkar
et al. (2008)
Endothelium
Notch3 Vascular smooth
muscle
VSMC null: decreased VSMC differentiation,
dilated aorta, and disorganized elastic lamina
Viable Ruchoux et al. (2003),
Domenga et al. (2004)
Pericytes R169C mutation: Notch3ECD domain
aggregates and GOM deposits in brain vessels,
reduced caliber of brain arteries, and cerebral
blood ﬂow
Notch4 Endothelium Global null: mainly undetectable vascular
malformations, with enhanced vascular
abnormalities when to crossed with Notch1 null
mice compared to Notch1 null alone
Viable Krebs et al. (2000)
Endocardium
Atrioventricular canal
Jag-1 Endothelium Global null: reduced VSMC maturation,
abnormal yolk sac and embryonic vascular
remodeling, cranial hemorrhaging
Lethal at E11.5–12 Xue et al. (1999)
VSMC
Heart
Dll-1 Arterial endothelium
late in development
Global null: hemorrhaging, increased venous EC
markers, reduced arterial EC markers, impaired
recovery of blood ﬂow after hindlimb ischemia
Lethal at E12 Hrabe de Angelis et al.
(1997), Limbourg et al. (2007)
VSMC, adult EC
Dll-4 Endothelium Global null: defective arterial branching, aortic
atresia, arterial regression, large artery stenosis,
abnormal yolk sac vasculature
Lethal at E9.5 Gale et al. (2004), Krebs et al.
(2004), Trindade et al. (2008)
Endocardium EC gain of function: enlarged dorsal aorta,
reduced vascular sprouting, proliferation,
migration, and sensitivity to VEGF
Lethal at E10
Gene targeting mutations in the Jag-2 and Dll-3 genes lead to developmental abnormalities, but no cardiovascular phenotypes have been reported. EC, endothelial
cell; VSMC, vascular smooth muscle cell.
pivotal role for Notch receptors/ligands in mediating endothe-
lial cell to smooth muscle cell communication, and inﬂuenc-
ing the phenotypic state of VSMC (Campos et al., 2002; Doi
et al., 2006; Anderson and Gibbons, 2007; High et al., 2008;
Tang et al., 2008; Boucher et al., 2011). Studies investigating the
function of Notch signaling in VSMC have yielded conﬂicting
results, describing both anti-differentiation (Morrow et al., 2005;
Proweller et al., 2005) and pro-differentiation functions for Notch
(Domenga et al., 2004; Tang et al., 2008; Boucher et al., 2011).
These discrepancies have been speculated to be a result of the
highly context-dependent nature and tight spatio-temporal reg-
ulation of Notch pathway components during development, in
the adult vasculature, and in response to physiological changes
in vivo. Mutations in the Notch pathway leading to human
pathology have recently been extensively reviewed (Fouillade et al.,
2012).
PHENOTYPIC FLEXIBILITY OF VASCULAR SMOOTH MUSCLE
CELLS
Many of the somatic cells that comprise an organism exist in a
terminally differentiated state, thereby maintaining steady state
expression of proteins that enable their mature function. The pri-
mary function of mature VSMC is to maintain vascular tone and
regulate blood pressure through constriction or dilation of the
vessel (Rensen et al., 2007). Quiescent VSMC are fully differenti-
ated, non-proliferative cells that express high levels of a subset of
genes required for their contractile functions. The central com-
ponent of the contractile apparatus in VSMC is comprised of
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FIGURE 2 | Neonatal mice with smooth muscle-specific Jag-1 gene
deletion exhibit patent ductus arteriosus. A conditional,
Cre-responsive Jag-1 allele was crossed to the SM22α-Cre strain
(TagIn-Cre) as described (Feng et al., 2010). To visualize the outﬂow tract
and ductus arteriosus, the left ventricles of control littermate (A) and
Jag-1 smooth muscle deletion (B) neonatal mice were injected with
silicone rubber injection compound (tinted yellow).While the ductus
arteriosus closed normally in the control mouse, it remained patent
(open) in the Jag-1 smooth muscle deletion mouse. Associated defects
in VSMC differentiation were also observed. DA, ductus arteriosus; LC,
left carotid artery; LSC, left subclavian artery; RC, right carotid artery;
RSC, right subclavian artery.
smooth muscle myosin heavy chain (SM-MHC) isoforms and
α-smooth muscle actin (SM-actin; Owens et al., 2004). The con-
tractile ﬁlament smoothelin B is exclusively expressed in mature
VSMC and represents a late stage differentiation marker (Chris-
ten et al., 1999). Smoothelin B is often rapidly down regulated
in proliferating VSMC cultures. Other well-characterized mark-
ers of matureVSMC include actin cross-linking protein transgelin
(SM22α), and the calcium binding protein and inhibitor of SM-
MHC intrinsic ATPase activity, calponin. Leiomodin-1, a gene
target of SRF/myocardin dependent transcription, was recently
described as a novel marker of contractile VSMC (Nanda and
Miano, 2012). Regulation of the actin cytoskeleton and contrac-
tile machinery of VSMC by SRF has previously been reviewed
(Miano et al., 2007). Events such as disruption of the endothelial
monolayer, exposure to growth factors (PDGF-BB, FGF), aberrant
interactions with the extracellular matrix, injury/wound healing,
and vascular remodeling can initiate cascades in VSMC leading
to a rapid down regulation of contractile proteins and acquisition
of a highly proliferative and migratory phenotype. While markers
of the proliferative VSMC phenotype are less well deﬁned than
contractile markers, the expression of tropomyosin 4 and myosin
heavy chain embryonic are observed during the proliferative state
of VSMC (Sung et al., 2005). Although Notch is appreciated as
one regulator of VSMC phenotype, there are conﬂicting data
describing its role in smooth muscle differentiation. The follow-
ing sections will discuss the current known mechanisms by which
Notch signaling affects VSMC phenotypic modulation.
MOLECULAR MECHANISMS OF NOTCH SIGNALING IN VSMC
Vascular smooth muscle cell express Notch1, Notch2, and Notch3
receptors while endothelial cells express Jag-1, Dll-4, and to some
extent in remodeling vasculature, Dll-1 (Table 1). Changes in the
levels of Notch receptors in VSMC and ligand expression patterns
by adjacent endothelial cells provide a means by which vascular
cells can communicate and respond appropriately to physiological
stimuli. In addition to Notch receptor activation by endothelial-
expressed ligands, VSMC expressed Jag-1 activates Notch1 on
endothelial cells to promote proliferation (Yang and Proweller,
2011), and thereby represents the importance of heterotypic cell
signaling between vascular cells via Notch. A variety of mecha-
nisms have been proposed to explain the discrepant phenotypes
in VSMC upon activation of Notch signaling. For example, it is
well documented that endothelial expression of Jag-1 is required
for activation of Notch3 on VSMC and maintenance of VSMC
maturation and contraction (High et al., 2008; Liu et al., 2009),
while others have shown a variety of mechanisms by which active
Notch signaling inhibits VSMC differentiation and the contrac-
tile phenotype (Havrda et al., 2006; Li et al., 2009a). Work from
our laboratory supports the former ﬁnding in that activation of
Notch receptors in human primaryVSMC using immobilized Jag-
1 promotes upregulation of contractile proteins (Boucher et al.,
2011; Figure 3A). Jag-1-mediated activation of VSMC markers
corresponded to a robust inhibition of proliferation (Figure 3B),
supporting a pro-differentiation effect for Jag-1/Notch signal-
ing in human VSMC. In addition, suppression of endogenous
Notch3 receptors using siRNA signiﬁcantly reduces endogenous
levels of SM-actin (Figures 3C,D), showing that basal Notch sig-
naling promotes the contractile phenotype. Although the precise
mechanism(s) of Jag-1/Notch-induced maturation is still poorly
understood, a number of studies have systematically investigated
themolecular pathways leading to the pro-differentiation and pro-
proliferative effects of Notch signaling in VSMC. Further studies
are required to additionally determine whether Jag-1 signaling
through other Notch receptors regulate the differentiated pheno-
type. We have observed strong expression of both Notch2 and
Notch3 receptors in the tunica media of large arteries derived
fromnormal human lung biopsies,while Notch1was undetectable
(Figure 4). Thus, further deﬁning Notch receptor expression and
function during normal and pathological settings will enhance
our understanding of the signals required formaintaining vascular
homeostasis.
Contractile genes in VSMC may be directly activated by tran-
scription factors promoting differentiation. The best characterized
is the SRF/myocardin complex, which is capable of potent
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FIGURE 3 | Jag-1/Notch3 signaling modulatesVSMC plasticity
toward maturation and contraction. Human aortic VSMC were plated
on immobilized recombinant rat Jag-1 Fc or Fc control for 48 h to activate
Notch receptors. Immunostaining reveals a signiﬁcant increase in the
expression of the contractile protein SM-actin in response to active
Notch signaling (A). BrdU incorporation into the nuclei of Jag-1 Fc
stimulated cells was signiﬁcantly reduced in comparison to Fc control
plated cells (B). (Green=BrdU positive nuclei, Blue=DAPI for total cell
count, n=15, p<0.01). Reduction of Notch3 levels via siRNA-mediated
knockdown (C) reveals a distinct reduction in endogenous SM-actin
levels after 72 h as compared to VSMC receiving a non-targeting control
probe (D).
FIGURE 4 | Expression of Notch receptors in human arteries. Human
lung biopsies were used for immunohistochemical analysis of Notch
receptors expressed by medial VSMC cells. (A) Representative images of
Notch receptors (green) and SM-actin positive cells (red) for Notch1 (left),
Notch2 (middle), and Notch3 (right). (B) Images were overlaid with DAPI
staining to show distribution and localization of Notch receptors within
SM-actin positive cells. The elastic laminae display some autoﬂuorescence.
transcriptional activation of VSMC marker genes through bind-
ing to highly conserved [CC(A/T)6GG] sequences, termed CArG
boxes, in their promoters (Treisman andAmmerer, 1992;McDon-
ald et al., 2006;Miano et al., 2007). Likewise,Notch signaling leads
to the regulation of hundreds of genes, some of which control
VSMC phenotype (Borggrefe and Liefke, 2012). Notch-responsive
CBF1 cis-elements are present in the promoters of the SM-MHC
(Doi et al., 2006) and SM-actin genes (Noseda et al., 2006), and
both are direct transcriptional targets of Notch. It remains unclear
whether CBF1/Notch requires higher order complex assembly
with SRF/myocardin at the promoter to activate transcription
or whether it can act independently. Our studies suggest that
Notch may be dependent on SRF activity to upregulate some tar-
get genes (SM-actin, SM-MHC), whereas it can independently
activate other targets (miR-143/145). In differentiation models of
10T1/2 mesenchymal cells toward the VSMC lineage, Jag-1/Notch
signaling up regulates de novo SM-MHC protein synthesis in a
CBF1-dependent manner (Doi et al., 2006), while chemical inhi-
bition of the γ-secretase complex (prevention of S3 cleavage and
NICD translocation to the nucleus) abrogates the Jag-1/Notch
speciﬁc induction of SM-MHC. Importantly, a requirement of
SRF/myocardin at the promoter was necessary for Notch-induced
synergistic activation. We observed a similar ﬁnding in that
over expression of a constitutively active Notch1ICD robustly
induces SM-actin expression in VSMC; however knockdown of
SRF was sufﬁcient to block this induction (Boucher et al., 2011).
It seems likely that communication between SRF/myocardin and
CBF1/Notch at contractile gene promoters may act in parallel, or
synergistically, to activate expression of VSMC markers.
Aside from direct transcriptional activation of VSMC speciﬁc
gene promoters by Notch signaling, recent evidence from our lab-
oratory shows transcriptional regulation of speciﬁc microRNAs
(miR) that are involved in acquisition of the contractile phenotype
inVSMC (Boucher et al., 2011). miR are short (∼22 nt) RNAmol-
ecules that are involved post-transcriptional regulation of protein
expression through mRNA destabilization and/or translational
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blockade (Baek et al., 2008). One intergenic miR cluster (con-
trolled by its own promoter) important in modulation of VSMC
plasticity encodes miR-143 and miR-145 (miR-143/145; Xin et al.,
2009). The miR-143/145 cluster plays an important role in mod-
ulation of VSMC phenotype through translational repression of
proliferative machinery (KLF4/5, Elk1; Boettger et al., 2009; Elia
et al., 2009; Xin et al., 2009). Although miR-143/145 is a known
transcriptional target of SRF/myocardin; Xin et al., 2009), we also
found that the miR-143/145 gene is a direct transcriptional tar-
get of Notch signaling. Transcriptional activation of miR-143/145
by Notch is CBF1-dependent, and independent of SRF/myocardin
in human VSMC (Boucher et al., 2011). Thus, Jag-1/Notch sig-
naling can activate miR-143/145 even with a mutant CArG box
in the promoter, but is reliant on binding of NICD/CBF1 com-
plexes to intact CBF1 consensus binding sites for its activation.
Induction of miR-143/145 by Jag-1/Notch signaling in human
VSMC is required forNotch-induced acquisition of the contractile
phenotype. These ﬁndings demonstrate that in addition to tran-
scriptional regulation of contractile gene promoters themselves,
Notch signaling controls expression of genes indirectly associated
with VSMC maturation.
NOTCH PROMOTES DIFFERENTIATION IN COOPERATION
WITH OTHER PATHWAYS
In addition to the shared functions of Notch and the
SRF/myocardin pathways, Notch cooperates with other signaling
mediators of VSMC differentiation. A recent study investigating
Notch signaling in murine epicardial development established a
connection with transforming growth factor beta (TGF-β) sig-
naling (Grieskamp et al., 2011). In this report, using aTbx18cre
driver to speciﬁcally delete CBF1 in the pro-epicardium, prog-
enitor cells failed to differentiate into coronary artery smooth
muscle cells. Additionally, conditional activation of Notch1ICD
forced the premature differentiation of epicardium cells into the
smooth muscle lineage. One potential mechanism they observed
was a lack of transforming growth factor beta (TGF-β) expression
in CBF1-deﬁcient cells, and the authors proposed that TGF-β1,
TGF-β2, and TGF-β3 ligands induced by active Notch signaling
led to co-activation of contractile genes to induce smooth muscle
differentiation from epicardium-derived cells. Our lab observed a
similar interaction in studies of co-activation of the Notch and
the TGF-β pathways in human VSMC (Tang et al., 2010). We
found that CBF1 interacts with phosphorylated SMAD2/3, and
this corresponds to increased phosphorylated SMAD2/3 activa-
tionof the genes encoding SM-actin, calponin1,andSM22α.Other
studies have also provided evidence supporting crosstalk between
Notch and TGF-β through their downstream effectors CBF1 and
SMAD2/3, respectively (Blokzijl et al., 2003; Zavadil et al., 2004).
NOTCH SIGNALING IS UPSTREAM OF REGULATORS OF
VSMC CONTRACTION AND TONE
Juxtaglomerular cells (also referred to as granular cells) repre-
sent a highly specialized smooth muscle-like cell type that sur-
rounds the afferent arteriole leading to the kidney glomeruli. The
primary function of these cells is to synthesize and secrete the
enzyme renin into the blood stream (Schweda and Kurtz, 2012).
In the circulation, renin converts the serum α2 globulin protein
angiotensinogen into angiotensin I. Angiotensin I is then fur-
ther processed in the lung by angiotensin converting enzyme to
produce angiotensin II, a potent vasoconstrictor that can play a
role in the onset of hypertension (Crowley et al., 2006; Gwath-
mey et al., 2012). Interestingly, the human, rat, and mouse pro-
moter/enhancer region of the Renin gene has a conserved binding
motif for CBF1. Signaling through Notch1ICD and CBF1 are suf-
ﬁcient to activate a promoter reporter construct in Cos-7 cells
in which multiple copies of the CBF1 motif in the rat Renin pro-
moter have been fused together (Pan andGross, 2005). In addition,
electrophoreticmobility shift assays revealed the presence of CBF1
protein bound to theRenin promoter inAs4.1 cells (Pan andGross,
2005). Further investigation of the regulation of RENIN expres-
sion by Notch signaling could provide a better understanding of
the factors contributing to excessive angiotensin II production and
the development of hypertension in humans.
Notch signaling also appears to play a direct role in regulating
renal vascular tone. A recent study tested effects of the vaso-
constrictors norepinephrine or angiotensin II on renal vascular
tone and resistance on a wild type or Notch3 null background
(Boulos et al., 2011). Unlike the predicted increase in renal vascu-
lar resistance in wild type mice, the renal vasculature in Notch3
null mice showed negligible changes in resistance. Isolation of the
afferent arteriole from Notch3 null mice revealed structural and
functional differences compared to wild type arterioles, including
reduced vessel wall thickness, and an aberrant contractile response
in response to angiotensin II. Notch3 null mice also were more
resistant to increased blood pressure after angiotensin II infusion,
although they were susceptible to heart failure. These observations
emphasize the importance of Notch signaling at a systemic level
in inﬂuencing and mediating the body’s response to endocrine
pathways.
POSITIVE FEEDBACK OF THE NOTCH PATHWAY
A positive feedback loop that potentiates Notch3 expression and
VSMCdifferentiationhas recently been identiﬁed (Liu et al., 2009).
Endothelial-expressed Jag-1 was shown to activate Notch3 expres-
sion in mural cells and ultimately lead to increased expression
of Notch3 and Jag-1 through a positive feedback loop as well
as induction of smooth muscle markers. Physical separation of
human dermal ﬁbroblasts from the endothelium, blockade of the
S3 cleavage using γ-secretase inhibitor or inhibition of ternary
complex formation using a dominant negative mastermind were
all sufﬁcient at inhibiting Notch3 positive regulation. The authors
were the ﬁrst to identify a mechanism by which Notch3 signaling
potentiates its own expression and the expression of its ligand. Fur-
thermore, a recent report has described a CBF1 cis-element within
the second intron of the Jag-1 locus that is responsive to exogenous
Jag-1 stimulation in primary VSMC isolated from murine aortic
arches (Manderﬁeld et al., 2012). The authors report a requirement
forNotch induction of Jag-1 in cardiac neural crest cell differentia-
tion toVSMC in the developing aortic arches. These ﬁndings shed
light on the importance of Notch signaling in not only potentiat-
ing VSMC development from mesenchymal progenitor cells, but
also the requirement of Notch-induced positive feedback loops for
proper vessel maturation and expansion of the VSMC layer in the
aorta through lateral communication.
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NEGATIVE FEEDBACK PATHWAYS OF VSMC
DIFFERENTIATION
The Notch pathway has a variety of molecular regulators that
repress its function, leading to the tight spatial regulation of
expressionof Notch target genes (Cave,2011). Repressionof differ-
entiation byHEY represents a pivotalway inwhichNotch signaling
can inhibit the contractile phenotype.An elaborate study by Prow-
eller et al. (2005) showed the induction of Notch signaling by
Jag-1 or over expression of a constitutively active Notch1ICD in
C3H10T1/2 cells robustly inhibited myocardin dependent expres-
sion of contractile gene expression through HEY2. HEY2 medi-
ated repression required the basic DNA binding domain and
C-terminal sequence. These ﬁndings may help explain why HEY2
null mice display decreased neointimal formation in response to
vascular injury (Sakata et al., 2004). Shortly after, it was shown
that HEY2 expression antagonizes SRF/myocardin binding to the
CArG box of contractile gene promoters both in vitro and in vivo
through a physical interaction with SRF (Doi et al., 2005). Our
laboratory showed that HEY expression antagonizes the activity of
NotchICD to induce SM-actin gene expression (Tang et al., 2008).
Using chromatin immunoprecipitation, we found that HEY2 dis-
rupted NotchICD/CBF1 increase in SM-actin protein by interfer-
ing with NotchICD/CBF1 binding to the promoter region of the
gene. This study provides a novel mechanism by which Notch is
capable of initially promoting a contractile phenotype in VSMC
before the onset of a negative feedback loop to antagonize the
effect. Presumably, such feedback mechanisms may help explain
the context-dependent nature of Notch signaling and the endoge-
nousmeans by whichNotch receptor activationmoderates its own
downstream effects. Thus, one function of HEY may be to antag-
onize Notch signaling as its levels accumulate in the cell, acting
to both propagate the Notch signal downstream, as well as pre-
vent further sustained signaling upstream from the receptor. We
also found that HEY expression was equally effective in suppress-
ing TGFβ1 induction of VSMC contractile genes. Therefore, HEY
factors appear to have a conserved function of inhibiting VSMC
differentiation via multiple pathways of SRF, Notch, and TGFβ
activation.
NOTCH RECEPTORS AND LIGANDS HAVE NON-REDUNDANT
FUNCTIONS
Although unique signaling pathways downstream of each Notch
ligand and receptor are not well deﬁned, it is clear that each has
somenon-overlapping functions. This is highlighted by the diverse
phenotypes obtained from targeted mutations or transgenic acti-
vation of these genes (Table 1). In addition, direct comparison of
ligand or receptor activity has suggested unique downstream func-
tions. For example, in osteoclastogenesis, Jag-1 and Dll-1 appear
to be either inhibitory or stimulatory signals, respectively (Sekine
et al., 2012). These opposing functions couldpartially be attributed
to a model where Jag-1 interacts with Notch1 and Dll-1 inter-
acts with Notch2 in the monocyte lineage to exert opposite cues
for osteoclastogenesis. Differences in ligand and receptor activity
have also been reported in regulation of the hematopoietic lineage
(Jaleco et al., 2001; de LaCoste andFreitas, 2006;VandeWalle et al.,
2011). Recent data suggest that this selectivity regulates Notch
functions in the cardiovascular system. During angiogenesis, Jag-1
and Dll-4 can have opposing activities with Jagged1/Notch cues
acting as pro-angiogenic signals, while activation of the Dll/Notch
pathway has anti-angiogenic consequences (Dufraine et al., 2008).
It will be of interest to determine how ligand-speciﬁcity and selec-
tive Notch activation may regulate the differentiated phenotype
of VSMC. This is especially crucial in situations of vascular dis-
ease and remodeling, where changes in Notch ligand and receptor
expression occur (Lindner et al., 2001).
Additionally, NotchICD can selectively associate with CBF1 at
separate and distinct cis-elements within the promoters of Notch
target genes. PDGFR has been identiﬁed as a downstream gene
target of Notch signaling in VSMC followed by over expression
of Notch1ICD or Notch3ICD (Jin et al., 2008). In VSMC, platelet
derived growth factor (PDGF)-BB signaling through the PDGF-
BB receptor-β (PDGFR) on VSMC represents a potent migratory
and proliferative signaling axis via the mitogen activated protein
kinase (MAPK) cascade (Inui et al., 1994; Graf et al., 1997). Acti-
vation of Notch in VSMC results in increased phosphorylation
and activation of PDGFR andAKT. Global Notch3 knockout mice
display a marked reduction in the arterial expression of PDGFR.
An intriguing observation in this report indicated that Notch1
and Notch3 regulate the PDGFR promoter through distinct CBF1
binding sites (Jin et al., 2008). Mutational analysis of CBF1 con-
sensus sites within a 1.5-kB PDGFR promoter element fused
to the luciferase gene, researchers found that Notch1ICD/CBF1
binds to the consensus motif at −256 to −249 upstream of the
transcriptional start site. In contrast, Notch3ICD/CBF1 regulates
the promoter through a consensus motif not located within the
PDGFR 1.5 kB promoter region. These ﬁndings present the pos-
sibility of distinct regulatory functions downstream of Notch
receptors, and stress the importance of changes to receptor expres-
sion during diseased and normal vascular states. Determining
the exact means by which receptor speciﬁcity is obtained will
present a great challenge moving forward. Many potential mecha-
nisms are already being considered, including the aforementioned
changes in the expression pattern of Notch ligands and recep-
tors, the speciﬁcity of ligands to the four Notch receptors, and
formation of distinct NotchICD-containing transcriptional com-
plexes at unique cis-elements. Additional levels of regulation are
expected to be the turnover of NotchICD proteins, the recruit-
ment of different histone acetyltransferases or deacetylases to the
transcriptional complex, regulation of non-canonical Notch sig-
naling, and the post-translational modiﬁcations of Notch (i.e.,
glycosylation).
NOTCH SIGNALING MEDIATES VSMC PROLIFERATION AND
NEOINTIMAL LESION FORMATION
Support for the involvement of Notch in mediating VSMC pro-
liferation and neointimal formation comes from a study in which
carotid artery ligations were used to induce the formation of a
neointima in mice harboring one of the following genotypes: a
general heterozygous deletion of Notch1 (Notch1+/−), a VSMC
speciﬁc heterozygous deletion of Notch1 (VSMC–Notch1+/−),
or a homozygous general deletion of Notch3 (Notch3−/−; Li
et al., 2009a). In this report, researchers show negligible differ-
ences in neointimal formation between wild type and Notch3−/−,
while Notch1+/− and VSMC–Notch1+/− resulted in post-carotid
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ligation decrease in neointimal lesion formation by 70%. The pro-
migratory and pro-proliferative effects of Notch1ICD over expres-
sion could be attenuated in HEY2 deﬁcient VSMC in vitro. Inter-
estingly, while Notch2 and Notch3 receptor expression remained
constant in bothmedial and neointimalVSMC, a transient expres-
sion of Notch1 was observed in neointimal VSMC (Li et al.,
2009a). Another recent report shows that expression of soluble
Jag-1, which acts as an inhibitor of Notch signaling, is sufﬁcient to
reduce VSMC proliferation and migration after balloon injury of
rat carotid arteries, which correlates to reduced neointimal lesion
formation. This effect was suggested to be via attenuation of the
Notch/HEY1 pathway (Caolo et al., 2011).
It is now known that certain chemicals can inﬂuence Notch1
expression levels and VSMC proliferation and migration. For
example, moderate alcohol intake has cardiovascular protective
effects mediated through Notch signaling in VSMC (Morrow
et al., 2010). In this report, human coronary artery VSMC were
treated with 25mmol/L ethanol (EtOH) daily for 7 days, which
led to a signiﬁcant decrease in cell proliferation. EtOH treat-
ment caused a decrease in Notch1 mRNA and ICD protein and
HEY1/2 expression while having negligible effects on Notch3. The
inhibition on VSMC proliferation by EtOH treatment could be
rescued uponover expression of Notch1ICDorHEY1. Lastly, feed-
ing EtOH to mice subjected to a partial ligation of the carotid
artery prevented the injury-induced induction of Notch1 and
reducedmedial, intimal, and adventitial volume signiﬁcantly from
injured mice not supplemented with alcohol. This study is unique
in that it provides a sound mechanistic link to Notch signaling
in mediating the cardioprotective effects associated with light to
moderate daily alcohol consumption (O’Keefe et al., 2007). The
same group also found thatmoderate alcohol consumption stimu-
lated endothelial cell proliferation andmigration (pro-angiogenic)
in vitro through activation of canonical Notch signaling, leading to
increased expression of angiopoietin and its receptor Tie2 (Mor-
row et al., 2008). Such studies emphasize the crucial role Notch
signaling plays in vessel homeostasis and the environmental factors
that contribute to its function in the cardiovascular system.
Finally, a requirement for Notch2 in promoting the expan-
sion of cardiac neural crest-derived VSMC around the devel-
oping outﬂow tracks has been reported (Varadkar et al., 2008).
While the mechanism supporting the observed phenotype is still
unclear, it emphasizes the spatio-temporal nature of Notch sig-
naling during VSMC development and its requirement for proper
vessel maturation. Collectively, it appears that transient changes in
Notch receptor expression are sufﬁcient to promote a pathological
phenotype characterized by increased migration and prolifera-
tion of VSMC in the neointima of injured arteries. Although
there may be some overlap of Notch receptor signaling, emerging
evidence provides insight into the possibility of receptor-speciﬁc
pathways and selective activation of downstream targets during
normal and pathological states. Transient expression of Notch1
may act as a primary mediator of VSMC proliferation/migration
during pathological states. Additional questions remain including
the causes of changes in Notch receptor expression during disease
states, whether Notch receptors exert differential functions in a
developing versus mature vessel, and the downstream factors that
specify the VSMC response to a speciﬁc Notch receptor.
NOTCH SIGNALING AFFECTS VSMC INTERACTION WITH THE
BASEMENT MEMBRANE AND MATRIX REMODELING
ENZYMES
Besides the contractile proteins themselves, the composition of
extracellular matrix (ECM) components and engagement with
distinct adhesion receptors on the cell surface play a distinct role
not only in regulating blood vessel development and the normal
and tumor angiogenic response (Silva et al., 2008; Astrof and
Hynes, 2009), but also in regulating the contractility of VSMC
(Ichii et al., 2001). VSMC secrete elastin, chondroitin sulfate, and
collagen types I, III, and V (Underwood et al., 1998). The makeup
of the ECM, as well as its degradation and synthesis by endothelial
cells and VSMC is essential for proper development and remodel-
ing of the vasculature. Perturbations in the rate of ECM turnover,
synthesis and secretion can lead to vascular pathology. For exam-
ple, disruption of vessel homeostasis can cause excessive ECM
deposition and generally correlates with a reduction in contrac-
tile proteins and increased VSMC proliferation and migration.
A recent investigation studied Notch regulation of VSMC adhe-
sion to the hemostasis-associated protein von Willebrand factor
(Scheppke et al., 2012). Mouse retinal vasculature models were
used to show that endothelial cell derived Jag-1 is required for
proper recruitment of VSMC to the developing vessel, and down-
stream induction of αVβ3 in VSMC enhanced adhesion to the
vonWillebrand factor in the endothelial cell basementmembrane,
leading to proper vessel maturation. Thus, Jag-1/Notch signal-
ing can increase VSMC maturation by regulating their adhesion
properties during vessel development and maturation. This ﬁnd-
ing builds upon previous studies indicating a role for endothelial
cell secreted soluble Jag-1, which lacks a transmembrane domain
and acts as a dominant negative inhibitor of Notch signaling, in
robustly decreasing NIH3T3 cell adhesion in migration (Lindner
et al., 2001).
Degradation of the ECM via matrix metalloprotease (MMP)
activity is a critical step leading to VSMCmigration, proliferation,
and neointima formation in injured arteries (Newby, 2006). Thus,
factors that regulate the expression and activation of MMPs likely
contribute toVSMCphenotype changes. Notch signaling has been
identiﬁed as a key regulator of MMPs in other systems includ-
ing regulation of MMP-9 in endothelial cells and their response
to VEGF (Funahashi et al., 2011), upregulation of MMP-13 in
chondrocytes (Blaise et al., 2009), and upregulation of MMP-9
in pancreatic cancer cells (Wang et al., 2006). It is not surprising
that Notch signaling can affect VSMC proliferation andmigration
through the regulation of MMPs. It has also been reported that
Notch can suppress MMP-2 and MMP-9 activity (Delbosc et al.,
2008), while the loss of the downstream Notch effector HEY2 in
VSMC alleviates repression of the MMP-10 promoter (Wu et al.,
2011). Interestingly, in other cell types, ectopic expression of mem-
brane type-1 MMPs induces the cleavage of Dll-1 and reduces
Notch signaling (Jin et al., 2011). Thus, MMP activity may be
responsive to Notch signals and also serve as a potential negative
feedback loop to suppress Notch signaling.
NOTCH SIGNALING IS INVOLVED IN VASCULAR PATHOLOGY
Atherogenesis is a pathological process in which damage to the
endothelium initiates changes in vessel wall homeostasis that
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lead to monocyte extravasation and secretion of inﬂammatory
cytokines capable of promoting VSMC proliferation and migra-
tion. The high rate of synthesis of ECM components by proliferat-
ing VSMC enables formation of a necrotic core and protective
ﬁbrous cap within the intima, resulting in propagation of the
atherosclerotic lesion. Notch signaling has been shown to mod-
ulate inﬂammatory pathways via repression of NF-κB (Oswald
et al., 1998;Wang et al., 2001), and Notch regulation of inﬂamma-
tion in atherogenesis has been addressed (Clement et al., 2007).
Notch activation by Delta-like-1 Fc chimeric proteins was suf-
ﬁcient to down regulate the secretion of phospholipase A2 and
prostaglandin E2 in response to Interleukin (IL)-1β, and thus had
an anti-inﬂammatory effect. In addition, IL-1β treatment, via NF-
κB activation, down regulates Notch3, Jag-1, HEY1, HEY2, and
HES1mRNA, and preventedNF-κB activation. Interestingly, there
was an observed increase in Notch1 mRNA. These results provide
evidence that Notch and inﬂammatory pathways interact during
disease, and describe novel anti-inﬂammatory and pro-quiescence
functions for Notch in VSMC.
Vascular calciﬁcation is the abnormal transformation of VSMC
leading to mineral deposition within the vascular wall (Vattikuti
and Towler, 2004). This condition may contribute to the patho-
genesis of atherosclerosis, hypercholesterolemia, end stage renal
disease, and diabetes. Unlike the apparent protective effects dur-
ing atherogenesis, Notch signaling mediates the activation of
osteogenesis-associated genes and induces VSMC calciﬁcation
(Shimizu et al., 2009). Co-culture of VSMC with Jag-1 or Dll-
4 expressing endothelial cells, or over expression of Notch1ICD
in human aortic VSMC resulted in a CBF1-dependent up reg-
ulation of MSX-1, and a concomitant increase in matrix min-
eralization. Expression of Notch1ICD can also enhance BMP-2
activation of MSX-2 by forming a complex with SMAD1 at the
promoter (Shimizu et al., 2011). On the other hand, Notch1 sig-
naling appears to prevent the osteoblastic-like pathways in VSMC
and protect against aortic valve calciﬁcation through repression of
BMP-2 (Nigam and Srivastava, 2009). In line with this, HEY1 was
found to physically interact with the osteoblast lineage-associated
transcription factor Runx2 and repress its transcriptional activ-
ity (Garg et al., 2005). Notch1 mutations abrogated this effect,
thus increasing the likelihood of calciumdeposition. These studies
demonstrate that the speciﬁc function of a single Notch receptor
must be deﬁned on a case-by-case basis, and that its function can
vary signiﬁcantly across the cardiovascular systemduring the onset
of disease.
Notch signaling has also been implicated in the pathogenesis
of pulmonary arterial hypertension (PAH). PAH is characterized
by narrowing of the small arteries of the lung, and increased pres-
sure in the lung vasculature, which leads to multi-symptomatic
clinical presentation that may result in heart valve disease, pul-
monary embolism, or congestive heart failure. Excessive VSMC
proliferation in the pulmonary arteries serves as a major factor in
the occlusion of luminal space and increase in pulmonary vascular
resistance. Recent reports indicate Notch3 as a marker and predic-
tor of the severity of PAH (Li et al., 2009b). In this report, Li and
colleagues show higher than normal levels of Notch3 and down-
stream target HES5 in lung VSMC derived from PAH patients.
Lung VSMC proliferation was shown to be dependent on the
Notch3–HES5 signaling axis. Notch3 nullmice are resistant to pul-
monaryhypertension,andblockadeof Notch signaling is sufﬁcient
to reverse PAH. Additionally, constitutive activation of the Notch3
pathway in VSMC lines inhibits contact-dependent growth inhi-
bition and decreases p27kip levels (Havrda et al., 2006). Gamma
secretase inhibitors have been proposed as a potential therapy to
decrease Notch3 signaling in lung VSMC. However, since gamma
secretase has numerous substrates (Haapasalo and Kovacs, 2011),
this strategy is likely to have undesired side effects, such as toxicity
to cell populations that rely on active Notch signaling (Riccio et al.,
2008). As our knowledge of Notch signaling increases, therapies
targeting speciﬁc receptors or pathways are likely to have strategic
advantages (Wu et al., 2010).
Cerebral Autosomal Dominant Arteriopathy with Subcortical
Infarcts and Leukoencephalopathy (CADASIL) is associated with
Notch3 mutations. CADASIL patients have non-atherosclerotic,
non-arteriosclerotic lesions in the small arteries of the cerebral
and systemic vasculature. Symptoms in humans include sus-
ceptibility to ischemic attacks, migraines, subcortical dementia
with pseudobulbar palsy, mood disorders, stroke, and ultimately
early death (Chabriat et al., 1995). Genetic analysis performed in
two unrelated families linked the disease to chromosome 19q12
(Tournier-Lasserve et al., 1993), which falls within the human
NOTCH3 gene. The Notch3ECD contains 34 EGF encoded by
exons 2–24,howevermutations in exons 3 or 4 account for approx-
imately 70% diagnosed with a CADASIL mutation (Joutel et al.,
1997). Abnormal accumulation of Notch3ECD was observed in
cerebral microvasculature of CADASIL patients close to granu-
lar osmiophilic material (GOM; Joutel et al., 2000). Others have
reported that Notch3ECD is amajor component of GOMdeposits
in thedermal vasculature of CADASILpatients (Ishiko et al.,2006).
These observations bring up the questions of how Notch3 muta-
tions may contribute to the formation of GOM deposits and the
progressive loss of VSMC. There is evidence that impaired glyco-
sylation of Notch receptor by Fringe enzymes occurs in mutant
Notch3 receptors in CADASIL (Arboleda-Velasquez et al., 2005),
and this may affect ligand interactions or trafﬁcking. Lastly, it
is noteworthy that not all human mutations in Notch3 resulting
in CADASIL can be recapitulated in mouse models. For exam-
ple, mutation of arginine 141 to cysteine in Notch3 represents a
common human mutation associated with CADASIL. However,
genetic alteration of the homologous arginine in the mouse gene
yielded no CADASIL manifestations (Lundkvist et al., 2005). The
activities of the Notch3 mutant proteins will require further study
to determine how impaired signaling yields the VSMC defects in
CADASIL.
Alagille syndrome (also referred to arteriohepatic dysplasia)
represents an autosomal dominant disorder in humans that can
result in profoundly negative systemic effects on the development
of the liver, kidney, eye, vertebrae, and cardiovascular system (Oda
et al., 1997). For the purposes of this review, we will focus on
the cardiovascular malformations associated with this syndrome.
Unlike CADASIL, which involves a mutation to Notch3 receptors,
Alagille syndrome is the result of a mutation within the extracellu-
lar or transmembrane encoding domain of JAG-1 at 20p12 locus
in humans (Li et al., 1997; Oda et al., 1997). Speciﬁcmutations can
cause aberrant glycosylation of Jagged1, resulting in dysfunctional
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trafﬁcking to the cell surface (Morrissette et al., 2001) and pre-
mature termination codons in the Jagged1 transcript, leading to
nonsense mediated decay. Truncated Jagged1 proteins may also
act as dominant negative signaling molecules (Boyer et al., 2005).
Whilemost diagnosed cases of Alagille syndrome are linked to null
mutations in JAG-1 (Spinner et al., 2001), hypomorphicmutations
inNOTCH2 have been identiﬁed in a subset of patients (McDaniell
et al., 2006). Interestingly, Jag-1+/− mice develop defects only in
the eye (Xue et al., 1999) and do not serve as adequate models for
Alagille syndrome. On the other hand, combining both a JAG-1
null allele and a Notch2 hypomorphic allele recapitulates symp-
toms of Alagille syndrome (McCright et al., 2002). Although the
vascular phenotypes associated with Alagille syndrome can vary, it
most commonly results in peripheral pulmonary stenosis. Of the
known cardiovascular manifestations, complex congenital heart
disease and intracranial bleeding contributedmost signiﬁcantly to
increasedmortality.Although still under investigation, it is feasible
that abnormal Jagged1 interaction with Notch2 has adverse effects
on the development of VSMC and the observed cardiovascular
pathologies.
CONCLUDING REMARKS
Notch signaling has profound effects on VSMC development,
proliferation, migration, and quiescence, and contributes to pro-
liferative vascular diseases and inﬂammatory conditions such as
atherosclerosis, arteriosclerosis, and angiogenesis. Multiple lig-
ands and Notch receptors are expressed in the vessel wall, both
developmentally and pathologically. While some clear molec-
ular pathways have been identiﬁed that link speciﬁc ligands,
receptors, and transcriptional output, there are still many out-
standing questions. It is unclear how activation of VSMC Notch
receptors with Jag versus Dll ligands regulates the VSMC con-
tractile phenotype. In addition, potential unique or overlapping
functions of Notch1, Notch2, and Notch3 signaling need fur-
ther clariﬁcation. Also, since VSMC are derived from a vari-
ety of sources embryonically and mature in all tissues, they
maintain a heterogeneity that affects their responsiveness to
Notch signaling. Finally, the role of Notch as a critical com-
ponent of an integrated microenvironment needs to take into
account interactions with cytokines, ECM, and other VSMC tran-
scriptional regulators. Answering these questions in the VSMC
lineage will contribute to our understanding of more global
questions related to Notch and cardiovascular homeostasis and
disease.
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